Seaport Therapeutics, Inc. (SPTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Seaport Therapeutics, Inc. (SPTX) closed at USD 16.68 on 2026-10-14, a change of -15.9 % over the past year, with a market capitalization of USD 942.14M.

Seaport Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Seaport Therapeutics, Inc. key figures

Previous close

USD 16.68 (2026-10-14)

1-year change

-15.9 %

Market cap

USD 942.14M

Enterprise value

USD 673.84M

P/E ratio (trailing)

-2.76

P/E ratio (forward)

-6.98

EPS (trailing)

-6.37

EPS (forward)

-2.52

PEG ratio

n/a

Price to book

2.23

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.95

Employees

58

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Seaport Therapeutics, Inc. and compare it with other stocks.